← Back to Treatments
🏅 FDA Orphan Designation

Azedra Ultratrace

Iobenguane I 131

Manufacturer: Progenics Pharmaceuticals, Inc.

Indicated for:
Neuroendocrine tumor of the rectumOrphanPineocytomaCarney-Stratakis syndrome

FDA-Approved Indications (3)

AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma w…

AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma w…

Population: adult and pediatric patients 12 years and older

AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma w…

Population: adult and pediatric patients 12 years and older

Indications & Usage

AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

💙 Support Programs

View all →
Azedra Ultratrace
Progenics Pharmaceuticals, Inc.
Azedra Ultratrace
Progenics Pharmaceuticals, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.